These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 9219265)

  • 21. Structural characterization of a human Fc fragment engineered for extended serum half-life.
    Oganesyan V; Damschroder MM; Woods RM; Cook KE; Wu H; Dall'acqua WF
    Mol Immunol; 2009 May; 46(8-9):1750-5. PubMed ID: 19250681
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Engineered human IgG antibodies with longer serum half-lives in primates.
    Hinton PR; Johlfs MG; Xiong JM; Hanestad K; Ong KC; Bullock C; Keller S; Tang MT; Tso JY; Vásquez M; Tsurushita N
    J Biol Chem; 2004 Feb; 279(8):6213-6. PubMed ID: 14699147
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences.
    Dall'Acqua WF; Woods RM; Ward ES; Palaszynski SR; Patel NK; Brewah YA; Wu H; Kiener PA; Langermann S
    J Immunol; 2002 Nov; 169(9):5171-80. PubMed ID: 12391234
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fc engineering: serum half-life modulation through FcRn binding.
    Olafsen T
    Methods Mol Biol; 2012; 907():537-56. PubMed ID: 22907373
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Over-expression of the bovine FcRn in the mammary gland results in increased IgG levels in both milk and serum of transgenic mice.
    Lu W; Zhao Z; Zhao Y; Yu S; Zhao Y; Fan B; Kacskovics I; Hammarström L; Li N
    Immunology; 2007 Nov; 122(3):401-8. PubMed ID: 17608809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Perspective-- FcRn transports albumin: relevance to immunology and medicine.
    Anderson CL; Chaudhury C; Kim J; Bronson CL; Wani MA; Mohanty S
    Trends Immunol; 2006 Jul; 27(7):343-8. PubMed ID: 16731041
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selection of IgG Variants with Increased FcRn Binding Using Random and Directed Mutagenesis: Impact on Effector Functions.
    Monnet C; Jorieux S; Urbain R; Fournier N; Bouayadi K; De Romeuf C; Behrens CK; Fontayne A; Mondon P
    Front Immunol; 2015; 6():39. PubMed ID: 25699055
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Addition of a mu-tailpiece to IgG results in polymeric antibodies with enhanced effector functions including complement-mediated cytolysis by IgG4.
    Smith RI; Coloma MJ; Morrison SL
    J Immunol; 1995 Mar; 154(5):2226-36. PubMed ID: 7868896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ligand binding and antigenic properties of a human neonatal Fc receptor with mutation of two unpaired cysteine residues.
    Andersen JT; Justesen S; Fleckenstein B; Michaelsen TE; Berntzen G; Kenanova VE; Daba MB; Lauvrak V; Buus S; Sandlie I
    FEBS J; 2008 Aug; 275(16):4097-110. PubMed ID: 18637944
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Investigation of the interaction between the class I MHC-related Fc receptor and its immunoglobulin G ligand.
    Raghavan M; Chen MY; Gastinel LN; Bjorkman PJ
    Immunity; 1994 Jul; 1(4):303-15. PubMed ID: 7889418
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of new models for the analysis of Fc-FcRn interactions.
    Gurbaxani BM; Morrison SL
    Mol Immunol; 2006 Mar; 43(9):1379-89. PubMed ID: 16183124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stoichiometry of the interaction between the major histocompatibility complex-related Fc receptor and its Fc ligand.
    Sánchez LM; Penny DM; Bjorkman PJ
    Biochemistry; 1999 Jul; 38(29):9471-6. PubMed ID: 10413524
    [TBL] [Abstract][Full Text] [Related]  

  • 33. pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling.
    Borrok MJ; Wu Y; Beyaz N; Yu XQ; Oganesyan V; Dall'Acqua WF; Tsui P
    J Biol Chem; 2015 Feb; 290(7):4282-90. PubMed ID: 25538249
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FcRn: the neonatal Fc receptor comes of age.
    Roopenian DC; Akilesh S
    Nat Rev Immunol; 2007 Sep; 7(9):715-25. PubMed ID: 17703228
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-affinity binding of the neonatal Fc receptor to its IgG ligand requires receptor immobilization.
    Vaughn DE; Bjorkman PJ
    Biochemistry; 1997 Aug; 36(31):9374-80. PubMed ID: 9235980
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IgG-Fc receptors and the clinical relevance of their polymorphisms.
    de Haas M
    Wien Klin Wochenschr; 2001 Oct; 113(20-21):825-31. PubMed ID: 11732118
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
    Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
    Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chimeric human-mouse IgG antibodies with shuffled constant region exons demonstrate that multiple domains contribute to in vivo half-life.
    Zuckier LS; Chang CJ; Scharff MD; Morrison SL
    Cancer Res; 1998 Sep; 58(17):3905-8. PubMed ID: 9731501
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies.
    Vaccaro C; Bawdon R; Wanjie S; Ober RJ; Ward ES
    Proc Natl Acad Sci U S A; 2006 Dec; 103(49):18709-14. PubMed ID: 17116867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative studies of rat IgG to further delineate the Fc:FcRn interaction site.
    Medesan C; Cianga P; Mummert M; Stanescu D; Ghetie V; Ward ES
    Eur J Immunol; 1998 Jul; 28(7):2092-100. PubMed ID: 9692877
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.